scholarly journals Immunogenicity of Quadrivalent HPV Vaccine in Adolescent Ghanaian Girls 36 Months After Vaccination

2021 ◽  
Author(s):  
Emmanuel Timmy Donkoh ◽  
Edward Tieru Dassah ◽  
Ellis Owusu-Dabo
Keyword(s):  
Adolescent Girls ◽  
Immunoglobulin G ◽  
Hpv Vaccine ◽  
Quadrivalent Vaccine ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Activity ◽  
Primary Role ◽  
Hpv 16 ◽  
Hpv 18

Abstract Introduction Available human papillomavirus (HPV) vaccines could have an important primary role in cervical cancer prevention once their long-term immunogenicity and safety are evaluated at the population level. The aim of this study was to optimize an assay to be used in evaluating the long-term durability of HPV vaccine response following a pilot vaccination of adolescent girls in Ghana. Methods A rapid, high-throughput, indirect enzyme-linked immunosorbent assay (ELISA) was evaluated for the detection and quantitation of anti-HPV L1 (late expression protein: types 6, 11, 16 and 18) immunoglobulin G (IgG) in human serum (n = 89). The performance of the assay was evaluated using serum collected from a cohort of pre-adolescent girls (n = 49) previously vaccinated with a quadrivalent vaccine and non-immune serum obtained from age-matched controls (n = 40). Results The seroprevalence of anti-HPV IgG antibodies was significantly higher among vaccinated than unvaccinated girls for both HPV − 16 (63.3% vs. 12.5%; p < 0.001) and HPV − 18 (34.7% vs. 20.0%; p = 0.042), respectively. Thirty-six months after receiving the third dose of vaccine, significantly higher mean anti–HPV-16 (0.618 vs. 0.145), anti–HPV-18 (0.323 vs. 0.309), and anti–HPV-6 (1.371 vs. 0.981) antibody levels were measured, compared to unvaccinated girls (all p < 0.05). A correlation between optical density and antibody activity indicated assay sensitivity to increasing levels of antibody activity. Conclusion We have successfully developed and implemented a robust and sensitive assay for the evaluation of antibody responses among immunized adolescent girls for monitoring future large-scale HPV vaccination studies in low-income settings. Our results demonstrated greater immunoglobulin G antibody activity within serum drawn from adolescent girls immunized 36 months prior.

scholarly journals Acute Plasmodium chabaudi chabaudi Malaria Infection Induces Antibodies Which Bind to the Surfaces of Parasitized Erythrocytes and Promote Their Phagocytosis by Macrophages In Vitro

1998 ◽  
Vol 66 (9) ◽  
pp. 4080-4086 ◽  
Author(s):  
Maria M. Mota ◽  
K. Neil Brown ◽  
Anthony A. Holder ◽  
William Jarra
Keyword(s):  
Parasite Clearance ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Activity ◽  
Parasite Line ◽  
Primary Role ◽  
Plasmodium Chabaudi ◽  
Species Specific ◽  
Cellular Immune ◽  
Variant Line

ABSTRACT CBA/Ca mice infected with 5 × 104 Plasmodium chabaudi chabaudi AS-parasitized erythrocytes experience acute but self-limiting infections of relatively short duration. Parasitemia peaks (∼40% infected erythrocytes) on day 10 or 11 and is then partially resolved over the ensuing 5 to 6 days, a period referred to as crisis. How humoral and cellular immune mechanisms contribute to parasite killing and/or clearance during crisis is controversial. Humoral immunity might be parasite variant, line, or species specific, while cellular immune responses would be relatively less specific. For P. c. chabaudi AS, parasite clearance is largely species and line specific during this time, which suggests a primary role for antibody activity. Accordingly, acute-phase plasma (APP; taken fromP. c. chabaudi AS-infected mice at day 11 or 12 postinfection) was examined for the presence of parasite-specific antibody activity by enzyme-linked immunosorbent assay. Antibody binding to the surface of intact, live parasitized erythrocytes, particularly those containing mature (trophozoite and schizont) parasites, was demonstrated by immunofluorescence in APP and the immunoglobulin G (IgG)-containing fraction thereof. Unfractionated APP (from P. c. chabaudi AS-infected mice), as well as its IgG fraction, specifically mediated the opsonization and internalization of P. c. chabaudi AS-parasitized erythrocytes by macrophages in vitro. APP from another parasite line (P. c. chabaudi CB) did not mediate the same effect against P. c. chabaudi AS-parasitized erythrocytes. These results, which may represent one mechanism of parasite removal during crisis, are discussed in relation to the parasite variant, line, and species specificity of parasite clearance during this time.

scholarly journals Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

2020 ◽  
Vol 21 (12) ◽  
pp. 1643-1652
Author(s):  
Carolina Porras ◽  
Sabrina H Tsang ◽  
Rolando Herrero ◽  
Diego Guillén ◽  
Teresa M Darragh ◽  
...  
Keyword(s):  
Costa Rica ◽  
Hpv Vaccine ◽  
Vaccine Trial ◽  
Hpv 16 ◽  
Long Term Follow Up

scholarly journals Single dose nonavalent HPV vaccine – need of the hour

2020 ◽  
Vol 10 (2) ◽  
pp. 871-873
Author(s):  
Soma Bandyopadhyay ◽  
Manidip Pal
Keyword(s):  
Single Dose ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
Cost Effective ◽  
Quadrivalent Vaccine ◽  
Carcinoma Cervix ◽  
Long Term Follow Up

HPV vaccination of the 9-14 years girl children is the answer to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single dose HPV vaccination, antibody titre remains good. Herd immunity also achieved by HPV vaccine. Hence single dose nonavalent HPV vaccination of mass people (sexually naive 9-14 years girl children) can provide almost 100% protections and this will be cost-effective also for developing country.  

scholarly journals Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial

2020 ◽  
Vol 112 (10) ◽  
pp. 1038-1046 ◽  
Author(s):  
Aimée R Kreimer ◽  
Joshua N Sampson ◽  
Carolina Porras ◽  
John T Schiller ◽  
Troy Kemp ◽  
...  
Keyword(s):  
Single Dose ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Vaccine Trial ◽  
Enzyme Linked Immunosorbent Assay ◽  
Virus Like Particle ◽  
Long Term Follow Up ◽  
Antibody Levels

Abstract Background The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. Methods HPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). Results Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9–11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. Conclusion More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.

scholarly journals Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Raul Storey ◽  
Joongho Joh ◽  
Amy Kwon ◽  
A. Bennett Jenson ◽  
Shin-je Ghim ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Small Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Small Cell Lung ◽  
Hpv 16 ◽  
Lung Cancers ◽  
Hpv Dna ◽  
The One ◽  
Nsclc Patients ◽  
Hpv 18

Background. A significant number of non-small-cell lung cancers (NSCLC) have human papillomavirus (HPV) DNA integrated in their genome. This study sought to further establish HPV’s possible etiologic link to NSCLC by evaluating an immune response to HPV’s oncogene, E7, in patients with NSCLC.Patients and Methods. Antibodies (IgG) in serum against E7 for HPV 16 and 18 in 100 patients with NSCLC were examined by enzyme-linked immunosorbent assay (ELISA).Results. Sixteen NSCLC patients were found to have a high titration of IgG for HPV oncogenic E7 protein. 23.5% of adenocarcinomas (AC,) and 15.4% of squamous cell carcinomas (SCC) were positive for IgG against HPV E7. HPV-18 (11%) had a slightly higher frequency than HPV-16 (6%). Of the six positive cases for HPV-16, 3 were AC, 2 SCC, and 1 NOS (not otherwise specified). For the 11 HPV-18 positives, 7 were AC, and 4 SCC. The one case with IgG against HPV 16 and 18 was AC. One case had high cross-reactive levels against E7 of HPV 16 and 18. Two (28%) of 7 patients who reported never smoking were positive for HPV, and 12 (13.6%) of 88 smokers were HPV positive.Conclusions. The study detected high levels of IgG against E7 in 16% of NSCLC patients. This adds evidence to a potential role of HPV in the pathogenesis of NSCLC.

scholarly journals Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial

2011 ◽  
Vol 18 (3) ◽  
pp. 418-423 ◽  
Author(s):  
Mel Krajden ◽  
Darrel Cook ◽  
Amanda Yu ◽  
Ron Chow ◽  
Wendy Mei ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Antibody Responses ◽  
Hpv 16 ◽  
Suitable Alternative ◽  
Human Papillomavirus 16 ◽  
Group 3 ◽  
Group 2 ◽  
Hpv 18 ◽  
Group 1

ABSTRACTHuman papillomavirus 16 (HPV 16) and HPV 18 antibody responses in a 2- versus 3-dose HPV vaccine (Gardasil) trial were measured by a pseudovirus neutralizing antibody (PsV NAb) assay and by the Merck competitive Luminex immunoassay (cLIA). Eight hundred twenty-four female subjects assigned to three dosing regimens (group 1, 9 to 13 years old; 2 doses, months 0 and 6 [n= 259]; group 2, 9 to 13 years old; 3 doses, months 0, 2, and 6 [n= 260]; group 3, 16 to 26 years old; 3 doses, months 0, 2, and 6 [n= 305]) had postvaccine responses assessed 1 month after the last dose. Of 791 subjects with baseline and 7-month sera, 15 (1.9%) and 9 (1.1%) were baseline seropositive for HPV 16 and HPV 18, respectively. All baseline-seronegative vaccinees seroconverted to both HPV 16 and HPV 18. Mean anti-HPV 16 levels were similar for groups 1 and 2 (for PsV NAb,P= 0.675; for cLIA,P= 0.874), and levels for both groups 1 and 2 were approximately 2-fold higher than that for group 3 (for PsV NAb and cLIA,P< 0.001). Mean anti-HPV 18 levels were approximately 1.4-fold lower in group 1 than in group 2 (for PsV, NAbP= 0.013; for cLIA,P= 0.001), and levels for both groups 1 and 2 were approximately 2.0- to 2.5-fold higher than that for group 3 (for PsV NAb and cLIA,P< 0.001). Pearson correlation coefficients for the assays were 0.672 for HPV 16 and 0.905 for HPV 18. Most of the discordant results were observed at lower cLIA signals. These results suggest that the PsV NAb assay could be a suitable alternative to cLIA for the measurement of postvaccine antibody responses.

scholarly journals Measurement of the Humoral Immune Response following an Incident Human Papillomavirus Type 16 or 18 Infection in Young Women by a Pseudovirion-Based Neutralizing Antibody Assay

2008 ◽  
Vol 15 (9) ◽  
pp. 1387-1390 ◽  
Author(s):  
Jane Steele ◽  
Stuart Collins ◽  
Kaisheng Wen ◽  
Gordon Ryan ◽  
Christothea Constandinou-Williams ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Response ◽  
Antibody Assay ◽  
Hpv 16 ◽  
Hpv 18

ABSTRACT We have evaluated a neutralizing antibody assay which uses human papillomavirus (HPV) type 16 (HPV-16) and HPV-18 pseudovirions carrying a secretory alkaline phosphatase reporter gene and which can potentially measure functionally relevant HPV type-specific neutralizing antibodies. The reproducibility of the assay was excellent; for HPV-16, the intra- and interassay kappa values were 0.95 and 0.90, respectively; and for HPV-18, the corresponding values were 0.90 and 0.90. This assay was used to describe the kinetics of the neutralizing antibody response in a cohort of 42 young women who were recruited soon after first intercourse and who first tested positive for HPV-16 DNA or HPV-18 DNA, or both, during follow-up. Most women seroconverted following the first detection of type-specific HPV DNA and remained seropositive until the end of follow-up. Our findings are broadly consistent with those of two other cohort studies which have measured the serological response following an incident infection by using the technically simpler virus-like-particle-based enzyme-linked immunosorbent assay.

Sign in / Sign up

Export Citation Format

Share Document